https://scholars.lib.ntu.edu.tw/handle/123456789/581923
標題: | HIV/HCV coinfection in Taiwan | 作者: | Hsu C.-S. JIA-HORNG KAO |
關鍵字: | Coinfection; Epidemic; Hepatitis C; HIV infection; Taiwan | 公開日期: | 2016 | 出版社: | Publicaciones Permanyer | 卷: | 18 | 期: | 4 | 起(迄)頁: | 193-197 | 來源出版物: | AIDS Reviews | 摘要: | Both human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection are important global public health problems with shared transmission routes. Although HIV/HCV coinfection is not uncommon, the prevalence rates vary significantly across different studies and regions. In Taiwan, injection drug users have become the major contributors to the HIV/AIDS epidemic since 2005. Because the prevalence of HCV infection is high in injection drug users, this HIV epidemic is also associated with a significant increase of HIV/HCV coinfection in Taiwan. To control Taiwan’s HIV epidemic, Taiwan Centers for Disease Control (CDC) launched a harm-reduction program in 2006. The HIV epidemic, the percentage attributed to injection drug users, and the prevalence of HIV/HCV coinfection gradually declined thereafter. In this article, we aimed to thoroughly examine the current literatures of HIV/HCV coinfection in Taiwan and hope to provide a better understanding of the needs for the management of this coinfection. We conducted a narrative review and searched for literature from PubMed, Ovid MEDLINE, and the Cochrane Library database untill August 2015. Studies relevant to the epidemiology and associated risk factors of HIV/HCV coinfection in Taiwan were examined and discussed. ? Permanyer Publications 2016. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85007283924&partnerID=40&md5=ddfb031dcdcd9cf04a7d5170b2655dd4 https://scholars.lib.ntu.edu.tw/handle/123456789/581923 |
ISSN: | 1139-6121 | SDG/關鍵字: | alanine aminotransferase; aspartate aminotransferase; gamma interferon inducible protein 10; antivirus agent; Article; CD4 lymphocyte count; disease transmission; drug abuse; hepatitis C; highly active antiretroviral therapy; human; Human immunodeficiency virus infection; Human immunodeficiency virus prevalence; liver fibrosis; mixed infection; needle sharing; prevalence; risk factor; seroconversion; Taiwan; complication; hepatitis C; HIV Infections; mixed infection; Antiviral Agents; Coinfection; Hepatitis C; HIV Infections; Humans; Risk Factors; Taiwan |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。